FDA
approval
· 2022-10-07
FDA Approved: JULUCA — Supplemental Application (ViiV Healthcare Company)
Summary
FDA approved a supplemental application for JULUCA (dolutegravir sodium and rilpivirine hydrochloride) from ViiV Healthcare Company.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for JULUCA (DOLUTEGRAVIR SODIUM AND RILPIVIRINE HYDROCHLORIDE)